| 000 | 01824 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514032401.0 | ||
| 264 | 0 | _c20020516 | |
| 008 | 200205s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/01.cir.0000014612.88433.62 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRukshin, Vladimir | |
| 245 | 0 | 0 |
_aComparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. _h[electronic resource] |
| 260 |
_bCirculation _cApr 2002 |
||
| 300 |
_a1970-5 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aArteriovenous Shunt, Surgical |
| 650 | 0 | 4 | _aBleeding Time |
| 650 | 0 | 4 |
_aBlood Coagulation _xdrug effects |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 |
_aHeparin _xpharmacology |
| 650 | 0 | 4 |
_aMagnesium Sulfate _xblood |
| 650 | 0 | 4 |
_aP-Selectin _xanalysis |
| 650 | 0 | 4 |
_aPeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aStents _xadverse effects |
| 650 | 0 | 4 |
_aThrombosis _xblood |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTirofiban |
| 650 | 0 | 4 |
_aTyrosine _xanalogs & derivatives |
| 700 | 1 | _aShah, Prediman K | |
| 700 | 1 | _aCercek, Bojan | |
| 700 | 1 | _aFinkelstein, Ariel | |
| 700 | 1 | _aTsang, Vivian | |
| 700 | 1 | _aKaul, Sanjay | |
| 773 | 0 |
_tCirculation _gvol. 105 _gno. 16 _gp. 1970-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/01.cir.0000014612.88433.62 _zAvailable from publisher's website |
| 999 |
_c11896446 _d11896446 |
||